.
. Systemic or regional chemotherapy is often used to treat these patients, but is relatively ineffective particularly with respect to survival. The poor response to chemotherapy may be a reflection of the hypovascular nature of most liver metastases which prevents access of therapeutic drug to the tumour (Kemeny et al., 1987; Taylor et al., 1979) .
Vasoactive drugs have a variety of effects on splanchnic and hepatic haemodynamics which may alter tumour blood flow and potentiate the delivery of a chemotherapeutic drug to liver tumour (Mattson et al., 1978 (Jenkins et al., 1984; .
We have developed a model of liver metastases in the rat using the HSN sarcoma. Our previous studies have demonstrated that tumour development in this model is associated with a decrease in portal venous inflow with no change in hepatic arterial flow. The tumours are supplied entirely from the hepatic artery, are histologically hypovascular compared to the surrounding liver parenchyma and do not show arteriosystemic shunting (Hemingway et al., 1989 
Results
The mean hepatic replacement by tumour was 27.12%. The haemodynamic effects of vasopressin infusion were as follows.
Changes in bloodflow
Hepatic arterial flow (Figure 1 ) was significantly decreased from 3.28 (1.82) ml min-' (Median (interquartile range)) to 1.65 (2.37) mlmin-' after vasopressin infusion (P<0.05). However, portal venous inflow (Figure 2 ) increased significantly from 2.12 (1.93) to 5.38 (7.08) ml min-' (P<0.01). (Goldberg et al., 1990) . Histological studies have shown that the blood vessels of tumours are undifferentiated and lack both muscular elements and adrenergic innervation (Mattson et al., 1978) . Nevertheless, alteration of intrahepatic haemodynamics may potentiate blood flow to hepatic tumour via a secondary effect, with a redistribution of the intrahepatic distribution of blood from high flow areas to low flow regions.
The low rate of vasopressin infusion (0.1 mU kg-' min-') used in this study, resulted in a systemic vasoconstriction, an increase in systemic blood pressure, but a decrease in hepatic arterial blood flow. Despite the reduction in hepatic arterial flow there was an increase in tumour blood flow which is in keeping with previous observations (Sasaki et al., 1985; Mattson et al., 1978) suggesting that hepatic tumour vasculature is less responsive to pharmacological manipulation than that in normal liver parenchyma. Furthermore, these experiments confirm the hypothesis that vasopressin by producing an intrahepatic vasoconstriction in liver resulting in a redistribution of arterial blood gives rise to a preferential delivery of blood to the tumour.
The mechanism by which vasopressin produces these effect on intrahepatic blood flow in tumour bearing rats is unclear. Previous studies have shown that the development of liver tumour causes marked changes in hepatic haemodynamics. We have previously demonstrated that in animals with HSN derived hepatic tumour, hepatic flow is unchanged, but portal venous inflow is significantly reduced (Hemingway et al., 1991) . This is confirmed in these experiments with a 40% reduction in the portal component of total liver blood flow. The alterations in portal venous inflow may modify the expected effects of vasopressin on hepatic haemodynamics. Vasopressin induced changes in hepatic arterial and portal venous flow in normal, cirrhotic and hypophysectomised animals are dose dependent (Jenkins et al., 1985) . A rate of infusion of vasopressin (0.1 mU g'I body weight) was chosen for this study which has been observed to produce an increase in arterial pressure and portal flow with a decrease in splanchnic vascular resistance (Jenkins et al., 1984) . Therefore, a vasopressin induced decrease in splanchnic resistance coupled with a rise in inflow pressure may account for the increase in portal venous inflow observed in rats with hepatic tumour, where portal venous inflow is already decreased as a result of the presence of tumour.
This study demonstrates that hepatic arterial vasoconstrictors such as vasopressin can increase effective tumour perfusion, thereby possibly potentiating the delivery of cytotoxic drugs administered regionally to the tumour. At the same time there may be a reduction in the exposure of the normal liver to the potentially hepatotoxic chemotherapeutic agents.
